Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cti Biopharm Corp (CTIC)

Cti Biopharm Corp (CTIC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lineage Cell: 2Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a loss of $6.5 million in its second quarter.

CTIC : 1.1300 (-5.83%)
CTI BioPharma Reports Second Quarter 2020 Financial Results

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended .

CTIC : 1.1300 (-5.83%)
CTI BioPharma Announces Enrollment of First Patient in COVID-19 PRE-VENT Phase 3 Clinical Trial

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hospitalized patients with severe...

CTIC : 1.1300 (-5.83%)
CTI BioPharma to Present at the Jefferies 2020 Healthcare Conference on Thursday, Jun. 4

, /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conference at . The conference will...

CTIC : 1.1300 (-5.83%)
Lineage Cell: 1Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a first-quarter loss of $8.4 million, after reporting a profit in the same period a year earlier.

CTIC : 1.1300 (-5.83%)
CTI BioPharma Reports First Quarter 2020 Financial Results

, /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended .

CTIC : 1.1300 (-5.83%)
CTI Biopharma Announces Initiation of Phase 3 PRE-VENT Study Evaluating Pacritinib in Hospitalized Patients with Severe COVID-19

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19. PRE-VENT, a randomized, double-blind,...

CTIC : 1.1300 (-5.83%)
Primary Myelofibrosis Pipeline Landscape Analysis, 2020 Featuring Novartis, Geron Corporation, NS Pharma, Actuate Therapeutics, Suzhou Zelgen Biopharmaceuticals, CTI BioPharma, Covance, and More - ResearchAndMarkets.com

The "Primary Myelofibrosis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

CTIC : 1.1300 (-5.83%)
GERN : 1.9600 (+6.52%)
NVS : 90.94 (-0.03%)
CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Needham Healthcare Conference at 10:40 a.m. EDT. The conference will be held...

CTIC : 1.1300 (-5.83%)
Lineage Cell: 4Q Earnings Snapshot

CARLSBAD, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Thursday reported a loss of $4.5 million in its fourth quarter.

CTIC : 1.1300 (-5.83%)
CTI BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2019.

CTIC : 1.1300 (-5.83%)
CTI BioPharma Announces Closing of Rights Offering

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the closing of its previously announced rights offering (the "Rights Offering"). At the closing, CTI BioPharma sold and issued an aggregate of 15,698,995...

CTIC : 1.1300 (-5.83%)
CTI BioPharma Announces Commencement of Rights Offering

CTI BioPharma Corp. (Nasdaq: CTIC) today commenced its previously announced rights offering to raise gross proceeds of approximately $60.0 million (the "Rights Offering"). Under the terms of the Rights...

CTIC : 1.1300 (-5.83%)
CTI BioPharma Announces Proposed Rights Offering

CTI BioPharma Corp. (Nasdaq: CTIC) today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights offering, investors as of February 13, 2020...

CTIC : 1.1300 (-5.83%)
CTI BioPharma Establishes Accelerated Approval Pathway for Pacritinib in Treating Myelofibrosis Patients With Severe Thrombocytopenia

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that following a meeting with the U.S. Food and Drug Administration ("FDA" or "the Agency"), CTI has reached agreement on an accelerated approval pathway...

CTIC : 1.1300 (-5.83%)
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Benefit in Myelofibrosis Patients with Severe Thrombocytopenia at the 61st American Society of Hematology Meeting

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the presentation of data from the Company's pacritinib development program, including results from the PAC203 Phase 2 clinical trial, at the 61st American...

CTIC : 1.1300 (-5.83%)
Lineage Cell: 3Q Earnings Snapshot

ALAMEDA, Calif. (AP) _ Lineage Cell Therapeutics, Inc. (LCTX) on Tuesday reported a third-quarter loss of $16.5 million, after reporting a profit in the same period a year earlier.

CTIC : 1.1300 (-5.83%)
CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting

CTI BioPharma Corp. (Nasdaq: CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at the 61st American Society of Hematology...

CTIC : 1.1300 (-5.83%)
CTI BioPharma Reports Third Quarter 2019 Financial Results

CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2019.

CTIC : 1.1300 (-5.83%)
CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment candidate, pacritinib. The...

CTIC : 1.1300 (-5.83%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar